With CHF Yael Waknine Medscape Medical News 2005. © 2005 Medscape June 8, 2005 (San Diego) — Testosterone replacement therapy significantly improves exercise capacity and quality of life in men with moderate to severe chronic heart failure (CHF), according to the results of a 12-month, double-blind, placebo-controlled trial presented here at ENDO 2005, the 87th Annual Meeting of the Endocrine Society.

A retrospective analysis by researchers at Beth Israel Deaconess Medical Center published in The New England Journal of Medicine found no causal relationship between testosterone replacement and prostate cancer or heart disease risk.

The comprehensive review of 72 studies, addresses the current controversy about testosterone replacement therapy and its potential health risks to men. "We reviewed decades of research and found no compelling evidence that testosterone

replacement therapy increases the incidence of prostate cancer or cardiovascular disease," said Abraham Morgentaler, MD, a urologist at BIDMC and associate clinical professor at Harvard Medical School. "Although it would be helpful to have data from long-term, large-scale studies, it must also be recognized that there already exists a substantial body of research on the effects of testosterone in men."

Cesare Carani, Andrea M. Isidori, Antonio Granata, Eleonora Carosa, Mario Maggi, Andrea Lenzi, and Emmanuele A. Jannini |Department of Endocrinology (C.C., A.G.), University of Modena, 41100 Modena, Italy; Department of Endocrinology (A.M.I., A.L.), University of Rome “La Sapienza”, 00161 Rome, Italy; Department of Endocrinology (M.M.), University of Florence, 50139 Florence, Italy; and Course of Endocrinology and Medical Sexology at the Department of Experimental Medicine of the University of L’Aquila (E.C., E.A.J.), 67100 L’Aquila, Italy Context: Thyroid hormones have a dramatic effect on human behavior.

Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency

Hernberg-Stahl E, Luger A, Abs R, Bengtsson BA, Feldt-Rasmussen U, Wilton P, Westberg B, Monson JP; KIMS International Board; KIMS Study Group.
Pharmacia International Metabolic Database.

Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency
Yael Waknine

Medscape Medical News 2005. © 2005 Medscape

June 10, 2005 (San Diego) — Twice-daily administration of high-dose recombinant human growth hormone–releasing hormone (GHRH) 1,44-amide stimulates growth hormone (GH) and insulin-like growth factor 1 (IGF-1) production, decreases abdominal visceral fat, and improves physical performance in postmenopausal women, according to the results of a prospective three-month pilot study presented here at ENDO 2005, the 87th Annual Meeting of the Endocrine Society.

Endogenous sex hormone levels and cognitive function in aging men
Is there an optimal level?

M. Muller, MD, PhD; A. Aleman, PhD; D.E. Grobbee, MD, PhD; E.H.F. de Haan, PhD; and Y.T. van der Schouw, PhD

Abstract—Objective:To determine whether endogenous sex hormone levels are associated with cognitive functioning in men. Methods: Cognitive performance was assessed in 400 independently living men between ages 40 and 80 in a population-based cross-sectional study.

Testosterone Injection: Enanthate - Cypionate – (T) Injections

Testosterone injections simply mean testosterone is injected directly into the body with the purpose if supplementing and raising/converting low T levels to higher healthy levels.  The key to effective and safe testosterone delivery is 1) stay as close to natural (bio-identical testosterone*) as possible and 2) take testosterone in small frequent doses.

Testosterone Cream - Increasing T Levels via Transdermal Creams

Testosterone starts to decline at about age 27 to 28.  Men will usually start feeling symptom at around age 35.  Some men will feel symptoms as early as age 30.  This condition is known as male menopause and also known as andropause.

Testosterone Replacement Therapy Does Not Increase Risk of Prostate Cancer
According to results recently published in The New England Journal of Medicine, testosterone replacement therapy for the treatment of hypogonadism does not appear to increase the risk of developing prostate cancer.

Study of testosterone replacement therapy not linked to prostate cancer, heart disease risk
'No compelling evidence' found